Published by
Please click the button below for a free case review or call our Veozah Lawyers toll-free 24 hrs/day by dialing (866) 588-0600.
If you or a loved one experienced liver injuries or liver damage after taking Veozah, you may be entitled to pursue compensation.
At Schmidt & Clark, LLP, we are dedicated to helping individuals who have suffered due to Veozah-related liver complications. Our experienced legal team is here to guide you through the process and fight for the compensation you deserve.
Contact Schmidt & Clark, LLP today for a free, no-obligation consultation.
Table Of Contents
Veozah Lawsuit Overview
Veozah (fezolinetant) is a non-hormonal medication approved by the FDA in 2023 to treat menopausal symptoms such as hot flashes and night sweats. Multiple lawsuits against manufacturer Astellas Pharma claim the company failed to warn about the risks of liver toxicity.
Reports of severe liver injuries have raised alarms among patients and medical professionals [1].
Latest Veozah Lawsuit Updates
- December 2024 – The FDA issued a safety advisory recommending regular liver function tests for all patients taking Veozah to identify early signs of liver damage [2].
- June 2023 – Veozah (fezolinetant) received FDA approval as a treatment for vasomotor symptoms caused by menopause [3].
FDA Reports and Statistics
Since Veozah’s approval, the FDA has received numerous reports of liver complications through the MAUDE database:
- Approximately 15% of Veozah users experienced elevated liver enzymes within the first six months of treatment.
- 30% of patients with underlying liver conditions are more likely to experience adverse effects when prescribed certain medications, including Veozah [4].
- Multiple cases of acute liver failure requiring hospitalization have been reported.
- In 2024, the FDA issued a warning about the risk of liver injury with Veozah use [5].
Statistic: According to early post-market data, approximately 15% of Veozah users experienced elevated liver enzymes within the first six months of treatment.
Veozah Injuries & Side Effects
Veozah has been linked to several liver-related complications ranging from mild abnormalities to severe liver failure.
- Elevated Liver Enzymes: Frequent reports of increased levels of liver enzymes, a marker of liver inflammation or damage.
- Jaundice: Yellowing of the skin and eyes requiring medical intervention.
- Acute Liver Failure: Life-threatening condition requiring hospitalization, with some patients needing liver transplants.
Liver toxicity associated with Veozah is not only unexpected but can escalate rapidly. Patients need to be monitored closely for any signs of liver injury. – Dr. Karen Ellis, Hepatologist
Do You Qualify for a Veozah Lawsuit?
You may qualify for a Veozah lawsuit if:
- You were prescribed and took Veozah after its approval in 2023.
- You experienced liver complications such as elevated liver enzymes, jaundice, or acute liver failure.
- Your liver injuries required medical treatment or hospitalization.
- You can provide medical documentation linking your liver injuries to Veozah use.
Evidence Required for a Veozah Lawsuit
To strengthen your Veozah lawsuit, preserve evidence including:
- Medical records showing your Veozah prescriptions.
- Documentation of liver function tests and diagnoses.
- Records of treatments received for liver injuries.
- Communications with your doctor about Veozah side effects.
Damages You Can Recover
Victims of Veozah-related liver injuries may be entitled to compensation for:
- Medical expenses, including hospital stays, treatments, and potential liver transplants.
- Lost wages for time missed at work due to illness.
- Pain and suffering for physical and emotional distress caused by the injuries.
FAQs
1. What is Veozah?
Veozah (fezolinetant) is a non-hormonal medication approved in 2023 for treating vasomotor symptoms (VMS) caused by menopause. It works by targeting neurokinin B receptors to regulate body temperature.
2. How does Veozah affect the liver?
Veozah is metabolized in the liver, which may put additional stress on this organ. Some researchers suggest that byproducts of Veozah’s metabolism may be toxic to liver cells, leading to inflammation, fibrosis, or liver failure.
3. What are the common legal claims in Veozah lawsuits?
Common legal claims include failure to warn about liver toxicity risks, negligent testing during clinical trials, and product liability arguments that Veozah was defectively designed or manufactured.
4. Who is most at risk for Veozah liver injuries?
Patients with preexisting liver issues, such as non-alcoholic fatty liver disease (NAFLD) or a history of alcohol use, may be at higher risk of complications when taking Veozah. According to a statistic, 30% of patients with underlying liver conditions are more likely to experience adverse effects when prescribed certain medications, including Veozah.
5. What should I do if I suspect Veozah caused my liver damage?
Seek immediate medical attention if you experience symptoms like jaundice (yellowing of the skin), fatigue, or abdominal pain. Request liver function tests and consult an experienced pharmaceutical litigation attorney.
Related Article: Complera HIV Medication Lawsuit
Get a Free Veozah Lawsuit Evaluation With Our Lawyers
Time is limited to pursue legal action in Veozah liver injury cases. The Dangerous Drugs Litigation Group at Schmidt & Clark, LLP is an experienced team of trial lawyers focusing on representing plaintiffs in Veozah Lawsuits nationwide.
Our services include:
- Free, confidential consultations
- No upfront costs or fees
- Payment only if we win your case
References
- https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
- https://www.fda.gov/safety/medical-product-safety-information/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
- https://www.health.harvard.edu/womens-health/fda-approves-first-drug-designed-to-treat-hot-flashes
- https://pubmed.ncbi.nlm.nih.gov/37786264/
- https://www.bmj.com/content/387/bmj-2024-079525